|
|
|
l |
Home | l | UK Companies | l | Genomics Topics | l | Species with sequenced Genomes | l | Contact |
l |
Recent Publications by Featured Genomics Companies: | ![]() | ||
| GlaxoSmithKline Medicines Research Centre | Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens.
The gut-hormone ghrelin endogenously binds to the ghrelin receptor (GHS-R)... | Department of Biology, Neurosciences CEDD, GlaxoSmithKline Medicines | Neurochem Int. 2008 Dec 11. DOI Direct Link |
| GlaxoSmithKline | Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens.
The gut-hormone ghrelin endogenously binds to the ghrelin receptor (GHS-R)... | Department of Biology, Neurosciences CEDD, GlaxoSmithKline Medicines | Neurochem Int. 2008 Dec 11. DOI Direct Link |
| GlaxoSmithKline | Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens.
The gut-hormone ghrelin endogenously binds to the ghrelin receptor (GHS-R)... | Department of Biology, Neurosciences CEDD, GlaxoSmithKline Medicines | Neurochem Int. 2008 Dec 11. DOI Direct Link |
| Pfizer Global Research and Development | Determination of a potent urokinase-type plasminogen activator, UK-356,202, in plasma at pg/mL levels using column-switching HPLC and fluorescence detection.
A rapid, sensitive and selective method using column-switching HPLC with... | Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global | J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Dec 3. DOI Direct Link |
| GlaxoSmithKline | Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia.
PURPOSE: Insulin-like growth factor-I receptor and phosphoinositide... | Authors' Affiliations: Oncology Biology and Metabolic Diseases, | Clin Cancer Res. 2009 Jan 1;15(1):217-25. DOI Direct Link |
| GlaxoSmithKline | New quinoline NK(3) receptor antagonists with CNS activity.
Lead optimisation starting from the previously reported selective... | Medicinal Chemistry, Neuroscience CEDD GlaxoSmithKline Research & | Bioorg Med Chem Lett. 2008 Dec 7. DOI Direct Link |
| GlaxoSmithKline | Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia.
PURPOSE: Insulin-like growth factor-I receptor and phosphoinositide... | Authors' Affiliations: Oncology Biology and Metabolic Diseases, | Clin Cancer Res. 2009 Jan 1;15(1):217-25. DOI Direct Link |
Patents: | ![]() | |
| Company | US Patent No. | Title |
| Syngenta | 7470837 | Inbred corn line G1105 |
| Syngenta | 7470835 | Soybean cultivar |
| Syngenta | 7470831 | Genetic method |
| GlaxoSmithKline | 7470782 | CASB618 polynucleotides and polypeptides and their use |
| GlaxoSmithKline | 7470782 | CASB618 polynucleotides and polypeptides and their use |
| AstraZeneca | 7470678 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
| Waters Corporation | 7470057 | Differential scanning calorimeter sensor and method |
| Syngenta | 7468453 | Production process of gamma-cyhalothrin |
| Syngenta | 7465805 | Isoxazoline derivatives and their use as herbicides |
| AstraZeneca | 7465795 | Compounds and uses thereof |
|